— Technology Description
Researchers at Washington University in St. Louis have developed a set of novel bile acid biomarkers to screen, diagnose, and monitor the progression of Niemann-Pick type C (NPC) disease. Current testing for this disease takes an average of three months, is invasive (a skin…
— Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy…
— Technology Description
Researchers in Andrew Yoo’s laboratory at Washington University have developed an antisense oligonucleotide targeting a miRNA (miR-29b-3p) as a treatment for Huntington’s disease (HD). Inhibiting miR-29b-3p promotes neuronal survival by rescuing neurons from deg…
— Background
Currently, biopsies are the only definitive method to diagnose a brain tumor. While PET-CT is used for initial imaging and monitoring of the tumor, after completion of treatments, a 6-8-week delay is usually implemented to avoid false-positive results. Yet, the delay could also result in…
— Technology Description
Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS).
Most patients with MS present with relapsing remitting MS (RRM…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
